---
layout: post
title: "Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products; Guidance for Industry; Availability"
date: 2026-02-05 18:55:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09170
original_published: 2023-05-01 00:00:00 +0000
significance: 8.00
---

# Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products; Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 01, 2023 00:00 UTC
**Document Number:** 2023-09170

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products; Guidance for Industry." The document provides guidance to assist sponsors in the clinical development of nicotine replacement therapy (NRT) drug products, including but not limited to those intended for smoking cessation and related chronic indications. This guidance finalizes the draft guidance of the same title issued on February 22, 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/01/2023-09170/smoking-cessation-and-related-indications-developing-nicotine-replacement-therapy-drug-products)
- API: https://www.federalregister.gov/api/v1/documents/2023-09170

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
